I find it staggering that the Cochrane researchers even came up with the idea that the question of long-term benefit could possibly be addressed by looking at short-term studies specifically designed to look at a different question.
In our first group of patients, there was only one, who asked (and got) his medications without the added expense of individual testing. I worryed about that for 2 weeks until he called up and said:
"Hey Doc, you don't have to worry about these medications"
I said "How's that?"
He said, "It used to be after a morning on the tools I'd have to take a nanna nap"
[He was a bricklayer and could only manage a morning's work before he had to have a sleep] (Translation from Australian slang)
Then he said, "Now I can go all day. It's like I'm 20 years younger. One of the young fellas even came up to me and asked 'Hey boss, what are you taking, can I get the connection?' I told him 'Not those kinda drugs mate'"
So while there are some patients who don't see fantastic improvements, and there are some patients that get side effects, in my experience the results of treatment are so clear cut you read the Cochrane thing and go "WTF are you guys smoking?"
G2, infected maybe in 1971?
Diagnosed HVnon-A non-B 1980s, revised to HVC 1990's.
Treatment naive. Fibroscan & bloods all normal ranges.
Viral load 7million,
began Redemption trial4, 12-week generic Sof/Vel (Incepta) 2017. Week 4 UND, Week 12UND, SVR24
Thank-yous to my doctor for the script, to Jan at FixHepC for wrangling, and to Dr Freeman for courage.
Kia kaha e hoa ma!
The following user(s) said Thank You: DrJames, Gaj
new Cochrane review - Hepatitis C: the key questions answered
6 years 7 months ago #24890
AASLD and IDSA would like to express our serious concerns regarding the recent Cochrane Group Review concluding that there is a lack of valid evidence supporting the benefit of direct acting antiviral (DAA) therapy for chronic infection with hepatitis C virus (HCV), and its supposition: “the possibility of potentially harming people with chronic hepatitis ought to be considered before treating people with hepatitis C with DAAs.” Our review of this Cochrane publication suggests significant flaws in this analysis, yielding a misleading and a harmful conclusion.
......even early data from the DAA experience support clear improvements in clinical outcomes that can be measured in the short term. Cure of HCV infection immediately reduces symptoms and organ dysfunction from severe extrahepatic manifestations including cryoglobulinemic vasculitis, a complication affecting up to 10 percent of HCV-infected patients.
Edit: EASL have also responded along similar lines:
"EASL, the European Association for the Study of the Liver, one of the world leading associations of liver specialists, feels compelled to express its serious concerns after the recent publication of a Cochrane Group systematic review entitled “Direct acting antivirals for chronic hepatitis C” by Jakobsen et al."